tranilast

Small moleculeexperimental

Tranilast is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s. — Wikipedia

Clinical trial activity

16 trials · 15 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2008 (NCT00818805)

Timeline

2000s

Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Jan 1, 2009
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Hypersensitivity

Studied for

Mechanism of action

CollagenINHIBITOR
Collagen inhibitor

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC

Mol. weight: 327.34 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaTranilast ↗
ChEMBLCHEMBL415324 ↗

Also known as

2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid
mk-341
mk-341
n-(3,4-dimethoxycinnamoyl)anthranilic acid
n-(3,4-dimethoxycinnamoyl)anthranilic acid
n-(3',4'-dimethoxycinnamoyl)anthranilic acid
rizaben
tranilast
tranilast
tranilast
tranilast
tranilast
tranilast
tranilast
tranilast
tranilast hydrate
tranilast hydrate
tranilast hydrate
tranilast hydrate
tranilast hydrate
tranilast hydrate
tranilast sodium
tranilast sodium salt
tranilastum
tranilastum

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06643689	Phase 2	Jan 1, 2025	Central South University, Hangzhou Third Hospital, Zhejiang University
NCT06689514	Early Phase 1 (Phase 1)	Nov 20, 2024	Jiao Tong University
NCT06307288	Phase 4	Oct 16, 2023	Jiao Tong University
NCT05626829	Phase 2	Jul 20, 2022	Southern Medical University
NCT05130892	Phase 4	Nov 15, 2021	Huazhong University of Science and Technology
NCT03923140	Phase 2	May 23, 2019	Chinese Academy of Medical Sciences
NCT03512873	Early Phase 1 (Phase 1)	Jun 30, 2018	Nanjing Medical University
NCT03528070	Early Phase 1 (Phase 1)	May 31, 2018	Nanjing Medical University
NCT03490708	Early Phase 1 (Phase 1)	Apr 30, 2018	Nanjing Medical University
NCT01109121	Phase 2	Jun 1, 2010	Nuon Therapeutics, Inc.
NCT01052987	Phase 2	Jan 1, 2010	Nuon Therapeutics, Inc.
NCT00995618	Phase 2	Sep 1, 2009	Nuon Therapeutics, Inc.
NCT00882024	Phase 2	Mar 1, 2009	Nuon Therapeutics, Inc.
NCT01003613	Phase 3	Feb 1, 2009	Hospital General Universitario de Castellón, Sao Jose do Rio Preto University, University of Brasilia, University of Sao Paulo
NCT00717808	Phase 1	Sep 1, 2008	Nuon Therapeutics, Inc., University of London
NCT00818805	Phase 4	Jul 1, 2008	Alcon

Showing 16 of 16 trials

Page 1 / 1

Organizations

Research & Development (15)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Nuon Therapeutics, Inc.	For profit	5	4	2	2008
Nanjing Medical University	Academic/Hospital	3	3	1	2018
Jiao Tong University	Academic/Hospital	2	2	2	2023
Alcon	For profit	1	1	1	2008
Central South University	Academic/Hospital	1	0	1	2025
Chinese Academy of Medical Sciences	Academic/Hospital	1	1	1	2019
Hangzhou Third Hospital	Academic/Hospital	1	0	1	2025
Hospital General Universitario de Castellón	Academic/Hospital	1	1	1	2009
Huazhong University of Science and Technology	Academic/Hospital	1	1	1	2021
Sao Jose do Rio Preto University	Academic/Hospital	1	0	1	2009
Southern Medical University	Academic/Hospital	1	1	1	2022
University of Brasilia	Academic/Hospital	1	0	1	2009
University of London	Academic/Hospital	1	1	1	2008
University of Sao Paulo	Academic/Hospital	1	0	1	2009
Zhejiang University	Academic/Hospital	1	1	1	2025

15 organizations

Page 1 / 1